'Education Research: Simulation training for neurology residents on acquiring tPA consent: An educational initiative'

The time-sensitive nature of acute ischemic stroke diagnosis and treatment with IV tissue plasminogen activator (tPA) presents a unique set of challenges for obtaining informed consent. Despite guideline recommendations that informed consent is indicated for thrombolysis,1 there is no accepted standardized consent process for thrombolytic administration and wide variability has been reported.2 Refusal of IV-tPA based on incorrect or incomplete understanding of its risks and benefits has the potential to affect morbidity after ischemic stroke, particularly for minority race/ethnic groups.